These afford flexibility for a pharmaceutical partner across the entire portfolio of drugs irrespective of stage of clinical development, says Dr
But obesity is not a trend, and your treatment should not be based on what is hottest this quarter
International journal of chronic obstructive pulmonary disease
Endocrinol Metab (Seoul) (2021) 36(1):229
Conflict of interest FG received research support from Eli Lilly, LifeScan, and Takeda and served as a consultant and author for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp and Dohme, Novo Nordisk, Roche Diabetes Care, and Sanofi
Tumour risk with once-weekly glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review